ReShape Lifesciences Relocates Principal Executive Offices
Ticker: HIND · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, address-change
TL;DR
ReShape Lifesciences moved its HQ to Irvine, CA on June 18, 2025.
AI Summary
On June 18, 2025, ReShape Lifesciences Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 18 Technology Drive, Suite 110, Irvine, CA 92618. This move from their previous San Clemente address signifies a potential operational shift or expansion.
Why It Matters
A change in principal executive offices can signal strategic shifts, operational changes, or growth initiatives for the company.
Risk Assessment
Risk Level: low — This filing is a routine administrative update regarding the company's address and does not involve significant financial or operational changes.
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- June 18, 2025 (date) — Date of earliest event reported
- 18 Technology Drive, Suite 110, Irvine, CA 92618 (location) — New principal executive offices
- San Clemente, CA (location) — Previous principal executive offices
FAQ
What is the new address for ReShape Lifesciences Inc.'s principal executive offices?
The new address is 18 Technology Drive, Suite 110, Irvine, CA 92618.
When was the change of address reported?
The change was reported on June 18, 2025.
What was the previous location of ReShape Lifesciences Inc.'s principal executive offices?
The previous location was San Clemente, CA.
What form was filed to report this change?
A Form 8-K was filed.
Is this a change in the company's legal jurisdiction of incorporation?
No, the filing states the company is incorporated in Delaware and this is a change in business address.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding ReShape Lifesciences Inc. (HIND).